Treatment of HIV infection with raltegravir

Author： Chirch Lisa M   Morrison Sidonie   Steigbigel Roy T  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.10, Iss.7, 2009-05, pp. : 1203-1211

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Raltegravir: In Treatment-Naive Patients with HIV-1 Infection

By Croxtall Jamie D.   Scott Lesley J.  

Drugs, Vol. 70, Iss. 5, 2010-03 ,pp. : 631-642

Adis International

Access to resources Recommend Favorite

Raltegravir: A Review of its Use in the Management of HIV Infection in Treatment-Experienced Patients

By Croxtall Jamie D.   Keam Susan J.  

Drugs, Vol. 69, Iss. 8, 2009-06 ,pp. : 1059-1075

Adis International

Access to resources Recommend Favorite

Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection

By Anker Mary   Corales Roberto B  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 1, 2008-01 ,pp. : 97-103

Informa Healthcare

Access to resources Recommend Favorite

Raltegravir: a guide to its use in HIV-1 infection

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 24, Iss. 6, 2008-06 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate

By Clercq Erik De  

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 17, 2009-12 ,pp. : 2935-2937

Informa Healthcare

Access to resources Recommend Favorite